On March 18, during a 2024 earnings call, WUXI APPTEC executives discussed the application of AI in the pharmaceutical Industry, stating that the Industry, particularly during the research phase, is exploring how to use AI to accelerate the development of Innovative Drugs. This is still in a relatively early stage, but we have enabled many such clients with our services. We believe that AI, as an innovative tool, can help the entire Industry improve efficiency and speed, and may likely create more opportunities for new drug development that were previously unachievable. We will also follow the trend and better provide exceptional services to our clients. WUXI APPTEC executives emphasized that there is a lot of information online about AI, especially concerning AI Innovative Drugs, but it should be made clear that WUXI APPTEC has never developed new drugs on its own and has not used AI to develop new drugs. Recently, there were reports online that WUXI APPTEC is developing AI Innovative Drugs through Chemistry42. We need to clarify that the technology mentioned here belongs to a biotechnology company and has no relation to WUXI APPTEC. As an integrated CRDMO service platform, we have always focused on providing enabling services, which will bring us more clients and business opportunities.